Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rexulti
Pharma
Celltrion buy, Rexulti CRL, Glenmark-Hengrui—Fierce Pharma Asia
Celltrion bought a Lilly plant in the U.S. The FDA turned down Lundbeck and Otsuka's PTSD application. Hengrui and Glenmark signed an ADC deal.
Angus Liu
Sep 26, 2025 10:00am
Otsuka, Lundbeck's Rexulti snubbed by FDA in PTSD
Sep 22, 2025 4:42pm
AbbVie's Skyrizi, Rinvoq led TV drug ad spending again in August
Sep 5, 2025 6:50am
Lundbeck stays positive on Rexulti PTSD use despite adcomm vote
Aug 15, 2025 10:50am
TV drug ad spending plummeted 20% in July
Aug 5, 2025 11:40am
FDA advisors overwhelmingly reject Lundbeck, Otsuka's PTSD drug
Jul 21, 2025 11:34am
